Coronavirus: Commission completes vaccines portfolio following t

The European Commission has today concluded exploratory talks with BioNTech-Pfizer to purchase a potential vaccine against COVID-19. BioNTech-Pfizer is the sixth company with which the Commission has concluded talks, following Sanofi-GSK on 31 July, Johnson & Johnson on 13 August, CureVac on 18 August and Moderna on 24 August. The first contract, signed with AstraZeneca, entered into force on 27 August.

Other news